SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT

6/3, 10:24 PM (Source: GlobeNewswire)

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY.RT).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Bristol-Myers and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 20, 2019, BMS issued a press release announcing the completion of its merger with Celgene Corporation (“Celgene”).  Under the terms of the merger, Celgene shareholders received for each Celgene share: 1.00 share of Bristol-Myers Squibb common stock; $50.00 in cash without interest; and one tradeable Contingent Value Right (“CVR”).  BMS’s press release advised investors that each CVR “will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are achieved.” 

On November 21, 2019, the CVRs began trading on the New York Stock Exchange under the ticker symbol “BMY.RT.”  On May 6, 2020, BMS issued a press release announcing, in relevant part, that “the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the biologics license application (BLA) for lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies. The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is November 16, 2020.” 

Then, on May 13, 2020, BMS issued a press release announcing receipt of “a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020.”  Following each of the foregoing disclosures, the value of BMS’s tradeable CVRs fell sharply, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.